In various animal studies, Epithalon was reported to have a range of potential benefits, including increased lifespan, improved immune function, and protection against age-related diseases
October 2023: FDA designates 17 peptides as Category 2, banning them from all pharmacy compounding
In summary: BPC-157 is a promising compound for different cytoprotective uses It is not FDA approved for human use There is not some shadow cabal blocking the use of BPC-157 - Financial incentives make it so that BPC-157 is challenging to push through the regulatory process - It will likely never receive FDA approval, but will be available in some form as oral supplement or through compounding pharmacies, with some modification This is not medical advice
You prioritize lean mass preservation
Best for tight budget: compounded tirzepatide vs semaglutide via verified telehealth
Lancet 356 , 17231727 (2000)